Maxim Group set a $6.00 target price on Sophiris Bio, Inc. (NASDAQ:SPHS) in a research report released on Monday morning. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Several other research analysts have also recently weighed in on the company. HC Wainwright set a $6.00 price objective on Sophiris Bio and gave the stock a buy rating in a research report on Friday. ValuEngine cut Sophiris Bio from a hold rating to a sell rating in a research report on Tuesday, June 13th. Finally, Rodman & Renshaw reaffirmed a buy rating and set a $6.00 price objective on shares of Sophiris Bio in a research report on Thursday, June 1st. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. The stock has a consensus rating of Buy and a consensus target price of $6.60.

Shares of Sophiris Bio (NASDAQ SPHS) traded up 1.09% during midday trading on Monday, reaching $1.85. The company had a trading volume of 72,267 shares. Sophiris Bio has a 52-week low of $1.80 and a 52-week high of $6.13. The firm’s market cap is $55.71 million. The company’s 50-day moving average is $2.06 and its 200-day moving average is $2.44.

Sophiris Bio (NASDAQ:SPHS) last posted its earnings results on Monday, May 15th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.09). Equities research analysts expect that Sophiris Bio will post ($0.39) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at https://www.thecerbatgem.com/2017/08/15/sophiris-bio-inc-sphs-given-a-6-00-price-target-at-maxim-group.html.

An institutional investor recently raised its position in Sophiris Bio stock. Vanguard Group Inc. increased its stake in Sophiris Bio, Inc. (NASDAQ:SPHS) by 1.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 731,437 shares of the biopharmaceutical company’s stock after buying an additional 7,600 shares during the period. Vanguard Group Inc. owned approximately 2.43% of Sophiris Bio worth $1,609,000 as of its most recent SEC filing. 5.50% of the stock is owned by institutional investors.

Sophiris Bio Company Profile

Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).

Analyst Recommendations for Sophiris Bio (NASDAQ:SPHS)

Receive News & Stock Ratings for Sophiris Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio Inc. and related stocks with our FREE daily email newsletter.